GlassScriptPhysician profile
Benjamin Barry
NPI 1033894084
$4,474.17
in general payments reported to CMS, 2019-2025
18 companies · $2,829 in 2025
The $2,829 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $333 · 2024: $1,312 · 2025: $2,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,521.94 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $520.61 | 2024-2025 | Caplyta |
| Alkermes, INC. | $503.57 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $391.03 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $340.85 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $333.37 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $227.40 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Livanova USA, INC. | $132.66 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Janssen Pharmaceuticals, INC | $126.02 | 2024-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $98.81 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $57.43 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $55.38 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $38.71 | 2024 | Rexulti |
| Tris Pharma INC | $34.24 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $29.33 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $22.42 | 2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $20.46 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.94 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.